Orbus Pharma, Generika aus Kanada - 500 Beiträge pro Seite
eröffnet am 10.05.04 20:57:34 von
neuester Beitrag 06.08.04 10:18:09 von
neuester Beitrag 06.08.04 10:18:09 von
Beiträge: 2
ID: 857.850
ID: 857.850
Aufrufe heute: 0
Gesamt: 802
Gesamt: 802
Aktive User: 0
Top-Diskussionen
| Titel | letzter Beitrag | Aufrufe |
|---|---|---|
| vor 58 Minuten | 5435 | |
| vor 48 Minuten | 4462 | |
| vor 1 Stunde | 2700 | |
| vor 42 Minuten | 1773 | |
| vor 44 Minuten | 1502 | |
| vor 1 Stunde | 1374 | |
| heute 06:53 | 1215 | |
| vor 47 Minuten | 1198 |
Meistdiskutierte Wertpapiere
| Platz | vorher | Wertpapier | Kurs | Perf. % | Anzahl | ||
|---|---|---|---|---|---|---|---|
| 1. | 1. | 18.371,47 | +0,85 | 267 | |||
| 2. | 3. | 171,64 | +0,02 | 80 | |||
| 3. | 2. | 10,320 | -2,46 | 75 | |||
| 4. | 4. | 1,1200 | -12,50 | 59 | |||
| 5. | 13. | 0,1995 | +3,64 | 51 | |||
| 6. | Neu! | 6,1720 | -0,29 | 47 | |||
| 7. | 6. | 7,0280 | +1,56 | 46 | |||
| 8. | 18. | 10,100 | -7,00 | 41 |
Feedback
Na, ist noch jemand drin???
Orbus Pharma Inc. Acquires Two Prescription Drug Products from Merck Frosst Canada & Co.
16:00 EDT Tuesday, May 04, 2004
TORONTO, ONTARIO--(CCNMatthews - May 4, 2004) - Orbus Pharma Inc. (TSX: ORB) today announced that it has acquired two prescription drug products for the Canadian marketplace from Merck Frosst Canada & Co. The two products are MIDAMOR(R) and MODURET(R). Combined 2003 sales for these two products were approximately $1.1 million dollars.
MIDAMOR(R) (amiloride hydrochloride tablets, USP) is an antikaliuretic agent with diuretic properties while MODURET(R) (hydrochlorothiazide and amiloride hydrochloride tablets) is a diuretic-antihypertensive.
Under the terms of the agreement, Merck Frosst will continue to distribute for a defined period after which Merck Frosst will communicate to its customers that Orbus Pharma has assumed distribution and is now responsible for the sales and marketing of the product in Canada. The financial terms were not disclosed.
About Merck Frosst Canada & Co.:
Merck Frosst Canada & Co. is subsidiary of Merck & Co., (NYSE: MRK) which is a global research-driven pharmaceutical products company. Merck discovers, develops, manufactures and markets a broad range of innovative products to improve human and animal health, directly and through its joint ventures. For further information please consult: http://www.merck.com.
About Orbus Pharma Inc.:
Orbus Pharma Inc., listed on The Toronto and Frankfurt Stock Exchanges under the symbols ORB and OBP respectively, pursues a strategy of generating revenue through the development of drug delivery systems and manufacture of off-patent pharmaceuticals, capitalizing on its ability to support the development and commercialization of a range of products at affordable costs.
FOR FURTHER INFORMATION PLEASE CONTACT:
Orbus Pharma Inc.
Jeffrey W. Renwick
President & CEO
(905) 943-9444
Orbus Pharma Inc. Acquires Two Prescription Drug Products from Merck Frosst Canada & Co.
16:00 EDT Tuesday, May 04, 2004
TORONTO, ONTARIO--(CCNMatthews - May 4, 2004) - Orbus Pharma Inc. (TSX: ORB) today announced that it has acquired two prescription drug products for the Canadian marketplace from Merck Frosst Canada & Co. The two products are MIDAMOR(R) and MODURET(R). Combined 2003 sales for these two products were approximately $1.1 million dollars.
MIDAMOR(R) (amiloride hydrochloride tablets, USP) is an antikaliuretic agent with diuretic properties while MODURET(R) (hydrochlorothiazide and amiloride hydrochloride tablets) is a diuretic-antihypertensive.
Under the terms of the agreement, Merck Frosst will continue to distribute for a defined period after which Merck Frosst will communicate to its customers that Orbus Pharma has assumed distribution and is now responsible for the sales and marketing of the product in Canada. The financial terms were not disclosed.
About Merck Frosst Canada & Co.:
Merck Frosst Canada & Co. is subsidiary of Merck & Co., (NYSE: MRK) which is a global research-driven pharmaceutical products company. Merck discovers, develops, manufactures and markets a broad range of innovative products to improve human and animal health, directly and through its joint ventures. For further information please consult: http://www.merck.com.
About Orbus Pharma Inc.:
Orbus Pharma Inc., listed on The Toronto and Frankfurt Stock Exchanges under the symbols ORB and OBP respectively, pursues a strategy of generating revenue through the development of drug delivery systems and manufacture of off-patent pharmaceuticals, capitalizing on its ability to support the development and commercialization of a range of products at affordable costs.
FOR FURTHER INFORMATION PLEASE CONTACT:
Orbus Pharma Inc.
Jeffrey W. Renwick
President & CEO
(905) 943-9444
Bei 1 Mio CAD Verlust im Quartal ist ein zusätzlicher Jahresumsatz von 1,1 auch nicht ausreichend.
Passiert nicht mehr mit der Aktie?
Passiert nicht mehr mit der Aktie?
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 267 | ||
| 80 | ||
| 75 | ||
| 59 | ||
| 51 | ||
| 47 | ||
| 46 | ||
| 41 | ||
| 41 | ||
| 38 |
| Wertpapier | Beiträge | |
|---|---|---|
| 34 | ||
| 34 | ||
| 32 | ||
| 31 | ||
| 30 | ||
| 25 | ||
| 23 | ||
| 20 | ||
| 19 | ||
| 19 |
